| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | Decades of established clinical evidence for pulsatile GnRH pump therapy in hypogonadotropic hypogonadism (CHH) and hypothalamic amenorrhea, including FDA-approved diagnostic and ovulation-induction indications. Score is scoped to these approved/established indications — not the TRT-adjunct community use case, where direct trial evidence is limited. |
20 / 25 |
| Sample Size | Cumulative evidence across CHH and ovulation-induction trials spans hundreds of patients over decades of clinical use, though individual trials are typically modest in size. |
12 / 20 |
| Replication | Pulsatile GnRH efficacy for restoring fertility in CHH has been independently replicated across multiple research centers and decades (Crowley, Dwyer, Pitteloud, and others), and confirmed against alternative protocols including FSH-pretreatment trials in JCEM. |
15 / 20 |
| Journal Impact Factor | Core literature published in JCEM (IF ~6.5) and Fertility and Sterility — strong, consistent reproductive endocrinology journal placement across the decades-long evidence base. |
12 / 15 |
| Funding Independence | Overwhelmingly academic and institutional research — decades of NIH and academic medical center-driven work on a generic, off-patent hormone, with no major commercial distortion identified. |
10 / 10 |
| Population Diversity | Studied in both men and women across multiple clinical contexts (CHH, hypothalamic amenorrhea), though concentrated in specific patient populations rather than broad general-population samples. |
3 / 5 |
| Researcher h-Index | Researchers including Nelly Pitteloud and William Crowley (Massachusetts General Hospital) are established leaders in reproductive endocrinology with strong academic profiles. |
5 / 5 |